Dysregulation of circulating protease activity

in Covid-19-associated superinfection

Fernando Dos Santos¹, Joyce B. Li², Nathalia Juocys^{1,3}, Rafi Mazor¹, Laura Beretta⁴,

Nicole G. Coufal⁵, Michael T.Y. Lam⁶, Mazen F. Odish⁶, Maria C. Irigoyen³,

Anthony J. O'Donoghue⁴, Federico Aletti^{7*}, Erik B. Kistler^{1,8*}

1

- ¹Department of Anesthesiology, School of Medicine, University of California, San Diego, La Jolla, CA,
- 3 U.S.A.
- ²Department of Bioengineering, University of California, San Diego, La Jolla, CA, U.S.A.
- ³Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
 (InCor-FMUSP), São Paulo, Brazil
- ⁴Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La
- 8 Jolla, CA, U.S.A.
- ⁵Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA,
 U.S.A.
- ⁶Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, U.S.A.
- ¹²⁷Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo, São José dos Campos, Brazil
- ⁸Department of Anesthesiology & Critical Care, VA San Diego Healthcare System, San Diego, CA,
 U.S.A.
- 15

16 * Correspondence:

- 17 Federico Aletti faletti@unifesp.br
- 18 Erik Kistler ekistler@health.ucsd.edu
- 19
- 20 Keywords: Covid-19, Sepsis, Proteolysis, Enzymatic activity, Peptidomics, Proteomics

22 Abstract

23 Infection by SARS-CoV-2 and subsequent COVID-19 can cause viral sepsis and septic 24 shock. Several complications have been observed in patients admitted to the intensive care 25 unit (ICU) with COVID-19, one of those being bacterial superinfection. Based on prior 26 evidence that dysregulated systemwide proteolysis is associated with death in bacterial septic 27 shock, we investigated whether protease activity and proteolysis could be elevated in COVID-28 19-induced sepsis with bacterial superinfection. In particular, we sought to assess the 29 possible implications on the regulation of protein systems, such as for instance the proteins 30 and enzymes involved in the clotting cascade.

Blood samples collected at multiple time points during the ICU stay of four COVID-19 patients
were analyzed to quantify: a) the circulating proteome and peptidome by mass spectrometry;
b) plasma enzymatic activity of trypsin-like substrates and five clotting factors (plasmin,
thrombin, factor VII, factor IX, factor X) by a fluorogenic assay.

35 Of the four patients, one was diagnosed with bacterial superinfection on day 7 after beginning 36 of the study and later died. The other three patients all survived (ICU length-of-stay 37 11.25±6.55 days, hospital stay of 15.25±7.18 days). Spikes in protease activity (factor VII, 38 trypsin-like activity) were detected on day 7 for the patient who died. Corresponding increases 39 in the total intensity of peptides derived by hydrolysis of plasma proteins, especially of 40 fibrinogen degradation products, and a general reduction of coagulation proteins, were 41 measured as well. A downregulation of endogenous enzymatic inhibitors, in particular trypsin 42 inhibitors, characterized the non-surviving patient throughout her ICU stay. Enzymatic activity was stable in the patients who survived. 43

44 Our study highlights the potential of multiomics approaches, combined with quantitative 45 analysis of enzymatic activity, to i) shed light on proteolysis as a possible pathological 46 mechanism in sepsis and septic shock, including COVID-19-induced sepsis; ii) provide

- 47 additional insight into malfunctioning protease-mediated systems, such as the coagulation
- 48 cascade; and iii) describe the progression of COVID-19 with bacterial superinfection.

50 **1. Introduction**

51 The Coronavirus disease (COVID-19) pandemic is caused by viral infection with the 52 coronavirus SARS-CoV-2. Affecting every organ of the body following initial infection of the 53 respiratory system, this highly contagious virus has contributed to the deaths of almost 5 54 million people to date. Despite the emphasis on COVID-19 research, our understanding of 55 the disease remains incomplete and therapeutic options are limited (1-7). Frequent and fatal 56 complications arising from SARS-CoV-2-induced sepsis include cytokine storm and coagulopathies (8,9). Less frequent (10), but not less dangerous, bacterial superinfections 57 make the clinical treatment of COVID-19 patients in the intensive care unit (ICU) even more 58 59 challenging, especially because of the lack of sound hypotheses as to the underlying 60 pathology and interplay between viral and bacterial infection and their clinical implications (11). 61

We have previously shown, in both animal and human studies, that a possible pathological 62 63 mechanism triggered by acute illness, including bacterial sepsis and septic shock, is 64 dysregulated proteolysis (12-15). Major protease-mediated systems are known to be affected in critical illness, including activation of the coagulation and complement cascades. To better 65 66 understand the possible relationship between systemic proteolysis occurring in shock. 67 including COVID-19-induced septic shock and the malfunction of these protease-mediated 68 systems, we have developed a complex, multimodal approach to assess protease activity 69 and proteolysis in plasma, consisting of quantitative enzymatic activity assays and mass 70 spectrometry-based multi-omics analyses of the circulating proteome and peptidome. The 71 utilization of these techniques has shown promising results in the ability to i) estimate in vivo 72 proteolysis in plasma as a marker of ongoing systemic proteolysis during shock (13,14) and 73 ii) detect circulating peptidase activity (16).

The hypothesis of this study was that a complex, dynamic description of plasma proteins and 74 75 the activity of some of their most important circulating enzymatic substrates can be leveraged 76 as a tool to shed light on the progression of COVID-19 and the risk for fatal complications, 77 especially in the presence of bacterial superinfection and diagnosis of sepsis and septic 78 shock. The specific goals that we aimed to investigate were to assess: 1) the patterns of 79 protease activity in the plasma of COVID-19 patients following admission to the ICU by means 80 of quantitative analysis of enzymatic activity; 2) the relationship between alterations in 81 protease activity over time during ICU stay and the development of bacterial superinfection; 82 3) the possible implications of dysregulated proteolysis on major protein systems (e.g., 83 clotting proteins and enzymes) by analysis of plasma proteomics and peptidomics.

84

85

86 2. Materials and Methods

87 2.1 Clinical measurements

This was a prospective observational study. The University of California, San Diego 88 Institutional Review Board (IRB) provided approval of the study conduct (IRB# 190699. 89 90 Protocol #20-0006); informed consent was obtained for the collection of blood samples and 91 de-identified use of the data. A convenience sample of four adult critically ill patients with 92 confirmed positive test for COVID-19 by real-time reverse transcription polymerase chain 93 reaction (RT-PCR) admitted to the Intensive Care Units (ICUs) at the University of California, San Diego Medical Center between April 01, 2020, and May 30, 2020, was enrolled in the 94 study. De-identified demographic and prior health history data were obtained. Three healthy 95 96 subjects were enrolled as a control group for enzymatic activity assays.

Standard laboratory measurements were obtained as necessary for optimal patient care by
the UC San Diego Medical Center for Advanced Laboratory Medicine (CALM) laboratories as
part of regular and usual care. No additional laboratory data were collected.

100 All non-standard laboratory assays, including protease activity assays and mass 101 spectrometry measurements were conducted off-site in academic research laboratories at 102 the University of California, San Diego. Patient blood samples (3-10mL) were collected in 103 sodium heparin (BD Vacutainer, REF: 366480) tubes. To prevent coagulation, the tubes were 104 inverted 10 times prior to transport at room temperature. Blood was processed within 4 hours of collection and kept at room temperature throughout the protocol. Polymorphprep[™] was 105 106 added to collected samples and centrifuged at 500g x 30 mins to separate plasma from white 107 blood cells per manufacturer's instructions (Progen) and transferred to new Eppendorf tubes 108 and centrifuged at 3731 x g for 5 minutes to remove any cellular debris. The supernatant was 109 transferred to new tubes and flash frozen in dry ice and 95% ethanol. Plasma was aliguoted and stored at -80° C for further analysis. 110

The clinical data acquisition and blood sample collection started on the day following protocol study consent (usually day of ICU admission) and was repeated on the following day and every other day thereafter until patient discharge or death.

114

115 2.2 Enzymatic activity

To test the enzymatic activity in COVID-19 plasma samples, we selected a variety of fluorogenic substrates, with a specific focus on enzymes with trypsin-like activity and clotting factors. All plasma samples were processed and analyzed simultaneously for each substrate, including healthy control plasma. The peptide sequences used in this assay were chosen as

120 substrates for coagulation factor enzymes, tryptic enzymes in general, as well as endopeptidase activity (Supplementary File 1). Briefly, a 384-well plate was used to combine 121 122 15µL of plasma (1/50 final dilution in PBS, pH=7.4) with 15µL of each substrate (5µM in PBS) 123 in triplicate wells and immediately measured for activity with a spectrophotometer (FilterMax 124 F5 Multi-Mode, Molecular Devices) with excitation of 360 nm and emission of 460 nm. Wells 125 were read every 2 minutes and 45 seconds for 4 hours and 50 minutes thereby generating 126 fluorescent activity progress curves that each contain 100 data points. Fluorogenic activity 127 was reported as relative fluorescence units per second using the slope from the progress 128 curve where the r² value was higher than 0.98. The activity was corrected by the dilution 129 factor. Due to the large variance measured between patients, all results shown are plotted as 130 the percentage of enzymatic activity relative to average of healthy control plasma samples on 131 a log₂ scale.

132

133 2.3 Proteomics and Peptidomics Analysis of COVID-19 Plasma

134 All plasma samples from the COVID-19 patients were subjected to a series of protein 135 extraction and pretreatment steps prior to mass spectrometry. The complete protocols for 136 plasma sample preparation, processing and data analysis steps can be found in 137 **Supplementary File 1.** Briefly, for proteomics measurements, proteins were precipitated 138 from the plasma samples, treated with denaturing, reducing, and alkylating reagents, and 139 enzymatically digested with trypsin. To quantify peptides in plasma, high molecular weight proteins were first removed following addition of methanol and the remaining peptide 140 141 guantified by LC-MS/MS. PEAKS Studio 8.5 (Bioinformatics Solutions, Inc.) proteomics 142 software was used for protein identification and quantification.

For the purposes of our study, the analysis of the circulating proteome and peptidome focused 143 144 on three main groups of proteins, according to their function: 1) coagulation; 2) complement 145 system, immune response and inflammation; and 3) endogenous protease inhibitors. Each 146 of these systems is known to be affected by acute illness, and their clinical management 147 poses significant challenges in critically ill patients. The proteins most relevant to our analyses 148 included: a) coagulation factors and fibrinogen for coagulation analysis; b) complement 149 factors, vascular endothelial growth factor receptor 2 (VEGF2) and C-reactive protein for 150 immune response and inflammation; c) serpins such as trypsin and chymotrypsin inhibitors, 151 thrombin and plasmin inhibitors, C1 inhibitors and heparin cofactor II for endogenous enzyme 152 inhibitors.

For proteome analysis, we used the log₂ ratio of each individual intensity measurement to the average of all sample intensities for each protein. Heat maps for the three main protein function groups considered for analysis were generated and analyzed using the web-based visualization software Morpheus (https://software.broadinstitute.org/morpheus). Identified proteins were hierarchically clustered with the one minus Pearson's correlation metric and average linkage method for each protein group. Columns were sorted by patient and ordered by day of sample collection.

For peptidomic analysis, the degree of overall proteolysis was estimated by the sum of all fragment intensities in a sample. Similarly, the proteolysis of a single protein was estimated by the sum of the intensities of the peptides generated by that protein. An online web tool, Peptigram (@Bioware - © University College Dublin) (17) was used to build cleavage maps representative of the number of peptides generated by a parent protein, abundance and length of each amino acid sequence, and cleavage site on the parent protein of origin.

166

167 **3. Results**

168 Patient characteristics are described in Table 1. The four patients randomly selected for 169 analysis were comprised of three males and one female and ranged in age from 29-88 years. Reflecting the overall demographics of the COVID-19 epidemic in San Diego, three of the 170 171 subjects were Hispanic. One patient, who will be referred to as "Patient 3" in the following, 172 was diagnosed with bacterial superinfection and subsequent sepsis on day 7 and died on day 173 16 of her ICU stay. The remainder (Patients 1, 2 and 4) were discharged from the ICU with a 174 mean ICU length-of-stay for all subjects of 11.25±6.55 days and mean hospital stay of 175 15.25±7.18 days. Body mass index (BMI) was 28.84±3.65 kg/m² (range: 29.4-32.14 kg/m²) 176 and self-described baseline health was either "fit" or "well".

177 All patients were initially treated with azithromycin. The three surviving subjects, who did not present with a bacterial superinfection, were also treated with ceftriaxone. Patient 3 was 178 treated after positive culture identification (Pseudomonas aeruginosa in urine and 179 180 Enterobacter aerogenes pneumonia) with piperacillin/tazobactam and later, with meropenem and vancomycin, after clinical failure to respond to infection. The three more critically ill 181 182 patients' pulmonary function reflected a diagnosis of Acute Respiratory Distress Syndrome 183 (ARDS) and these patients were intubated and placed on mechanical ventilation for at least 184 some period of their ICU stay. These three patients also required the application of 185 vasopressor agents to maintain hemodynamic stability.

Pertinent laboratory data are reported in **Table 2** and reflect a relatively homogeneous distribution of their hemogram as well as metabolic laboratory results (not shown) and coagulation panel. It should be noted that the outlying results in Patient 3's white blood count (WBC) of 19.8x109/L, hemoglobin of 6.4 g/dL, and platelet count of 461 x103 μ L/ml are from the final day of the patient's hospital stay and represent her moribund condition.

191	Enzymatic activity data are reported in Figure 1 (coagulation enzymes) and in Figure 2
192	(trypsin-like enzymes and exopeptidases). Figure 1 shows that plasmin activity remained
193	stable over time and between patients, serving as internal control of enzymatic activity.
194	Thrombin and Factor IX activity showed an increasing trend over the first five days of ICU
195	admission followed by decrease. Factor X activity decreased over time in Patients 1 and 2
196	compared to day 2 and increased in Patients 3 and 4. The main finding was the marked
197	increase in Factor VII activity and tryptic-like activity, particularly at a terminal Val-Arg (Figure
198	2) in Patient 3 on day 7, when bacterial superinfection was diagnosed.
199	Figure 2 also shows static amino- peptidase activity (Met-AP (Vivitide®, Gardner, MA)),
200	serving as a de facto negative control for the assay.
201	
202 203	Figure 1. Clotting enzyme activity during the ICU stay of the four patients enrolled in the study.
204	
204 205 206 207 208	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study.
204 205 206 207 208 209	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study.
204 205 206 207 208 209 210	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study. Patient 3 exhibited a reduction in several plasma coagulation proteins such as coagulation factors V and XI on day 7 and thereafter, and a concomitant increase in the expression of
204 205 206 207 208 209 210 211	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study. Patient 3 exhibited a reduction in several plasma coagulation proteins such as coagulation factors V and XI on day 7 and thereafter, and a concomitant increase in the expression of fibrinogen, plasma kallikrein and von Willebrand factor (Figure 3A). Overall, there were mild
204 205 206 207 208 209 210 211 212	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study. Patient 3 exhibited a reduction in several plasma coagulation proteins such as coagulation factors V and XI on day 7 and thereafter, and a concomitant increase in the expression of fibrinogen, plasma kallikrein and von Willebrand factor (Figure 3A). Overall, there were mild changes over time in plasma from Patient 3 in the abundance of proteins involved in the
204 205 207 208 209 210 211 212 212 213	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study. Patient 3 exhibited a reduction in several plasma coagulation proteins such as coagulation factors V and XI on day 7 and thereafter, and a concomitant increase in the expression of fibrinogen, plasma kallikrein and von Willebrand factor (Figure 3A). Overall, there were mild changes over time in plasma from Patient 3 in the abundance of proteins involved in the immune and inflammatory response (Figure 3B), as shown by diverging trends of increase
204 205 206 207 208 209 210 211 211 212 213 214	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study. Patient 3 exhibited a reduction in several plasma coagulation proteins such as coagulation factors V and XI on day 7 and thereafter, and a concomitant increase in the expression of fibrinogen, plasma kallikrein and von Willebrand factor (Figure 3A). Overall, there were mild changes over time in plasma from Patient 3 in the abundance of proteins involved in the immune and inflammatory response (Figure 3B), as shown by diverging trends of increase and decrease of the complement factors. Interestingly, starting on day 7 ficolin-1 and VEGF
204 205 206 207 208 209 210 211 212 213 214 215	Figure 2. Trypsin-like and amino-peptidase activity during the ICU stay of the four patients enrolled in the study. Patient 3 exhibited a reduction in several plasma coagulation proteins such as coagulation factors V and XI on day 7 and thereafter, and a concomitant increase in the expression of fibrinogen, plasma kallikrein and von Willebrand factor (Figure 3A). Overall, there were mild changes over time in plasma from Patient 3 in the abundance of proteins involved in the immune and inflammatory response (Figure 3B), as shown by diverging trends of increase and decrease of the complement factors. Interestingly, starting on day 7 ficolin-1 and VEGF 2 were increased in Patient 3, while the trend was less apparent and characterized by some

217	in expression over time in all four patients. A general trend towards a reduction in the				
218	expression of enzymatic inhibitors, in particular of endogenous trypsin inhibitors, was				
219	observed in Patient 3, (Figure 3C). Thrombin inhibitors such as antithrombin-III and heparin				
220	cofactor II were also characterized by lower abundance in Patient 3 compared to the survivo				
221	at all time points.				
222	The proteins characterized by the most evident trends (over time and between patients) are				
223	highlighted in the heat maps in Figure 3 with a diamond sign next to the protein name. For				
224	the complete proteome profile, please see Supplementary File 2.				
225					
226	Figure 3.				
227	Heatmaps of the most significant proteins involved in coagulation (A), immune or				
228	inflammatory response (B), and endogenous enzymatic inhibition (C) detected in COVID-19				

patient plasma. Data are presented as Log2 ratio of the averages. Rows of identified proteins
were hierarchically clustered with the one minus Pearson's correlation metric and average
linkage method for each protein group. Columns were sorted by patient and ordered by day
of sample collection. The heatmaps were obtained using the visualization software Morpheus
(https://software.broadinstitute.org/morpheus/).

234

The sum of the intensities of all the peptide fragments detected at each time point from a total 235 236 of 233 source proteins suggests marked proteolytic activity in Patient 3 on day 7 (Figure 4A). 237 This ongoing protein degradation was particularly evident in fibrinogen- α and fibrinogen- β (Figure 4B and 4C). Of note, peptides derived from α2-antiplasmin had a characteristic trend 238 in Patients 1, 3 and 4, with a progressive increase until day 5, followed by an abrupt reduction 239 and a progressive increase thereafter. Figure 4E shows the unique patterns of protein 240 241 cleavage for fibringen- α obtained by Peptigram analysis and the size and location of the 242 fragments that suggest that the enhanced proteolytic activity seen on day 7 in Patient 3

increases the amount of circulating fibrinopeptide A (FPA). The link to the complete peptidome profile on Peptigram can be found in **Supplementary File 1**.

245

246

Figure 4.

Total intensity as the sum of the intensities of the peptides detected in COVID-19 patient plasma: a) from the whole proteome (A); b) from fibrinogen- α (B); c) from fibrinogen- β (C); d) from alpha-2-antiplasmin (D). Peptigram representation of the cleavage pattern of fibrinogen- α in the four patients at each time point (E).

- 251
- 252

253 4. Discussion

Omics approaches (metabolomics, proteomics, peptidomics, transcriptomics, genomics) to study disease, including acute illness, have become increasingly popular due to the unique multiscale insights they provide that can result in better targeted treatments (12,14,18-23). Several contributions have already been made to the field of COVID-19 by proteomics (24-

258 27).

259 We have previously leveraged -omics analyses to test the hypothesis that dysregulated systemic proteolysis occurs in circulatory shock using a peptidomic-based assay, which 260 estimates proteolysis by assessing the abundance and count of circulating peptides (13,14). 261 262 Analysis of the plasma peptidome by this method showed an association between enhanced 263 proteolysis and death (14) in septic shock caused by bacterial infection. Therefore, we investigated whether a similar association may also be found in viral sepsis caused by 264 265 COVID-19 infection with bacterial superinfection developing over the course of the ICU stay. To better characterize and quantify the dynamic aspect of systemic intravascular proteolysis, 266

proteolytic activity generated by proteases that are known to be activated in acute illness,
such as clotting factors and other serine proteases were measured.

269 Protease activity patterns showed a marked increase of Factor VII and Factor IX activity on 270 day 7 in the patient who died of superinfection. In particular, the spike in Factor VII activity 271 was unique amongst our sample cohort and represents an 80-fold increase in activity relative 272 to that found in healthy control plasma. Further, the same trend in activity was also found in 273 two substrates identified by the C-terminus cleavage sites Val-Arg and Leu-Arg, representative of tryptic-like proteolytic activity. Although the activity of all four substrates 274 (Factor VII, Factor IX, Val-Arg, Leu-Arg) tended to decrease after the initial increase, the peak 275 276 on day 7 in Patient 3 coincided with the diagnosis of bacterial superinfection, and with an 277 increase in peptide abundance, particularly from fibrinogen.

278 Most fibringen-derived peptides in Patient 3 on day 7 originated from the Fibringeptide A (FPA) domain, located at the N-terminal region of the fibrinogen Aa chain (Aa 20-35), which 279 280 is normally generated by thrombin cleavage of fibrinogen upon activation of the clotting 281 cascade. FPA is a known biomarker of the activation of the coagulation system and was 282 shown to be related to elevated inflammation in sepsis, including COVID-19-induced sepsis 283 (28). Although thrombin was not shown to be overactivated, other serine proteases may 284 contribute to fibrinogen cleavage at typical thrombin cleaving sites. Further, the 285 underexpression of antithrombin-III and heparin cofactor II also hint at a decreased capacity 286 to regulate thrombin and other protease activity, regardless of thrombin expression and 287 activity levels. Consistent with our prior findings on enhanced proteolysis over time in patients 288 who died of septic shock (14), these findings may indicate a possible relationship between a 289 surge in proteolytic activity in concert with impairment of the coagulation cascade and 290 worsening overall clinical course after development of bacterial infection following the initial

progression of COVID-19 infection. This was apparent clinically in Patient 3 who had been on either phenylephrine or norepinephrine (but not both) for hypotension from admission to the ICU, and on day 7 necessitated the addition of two simultaneous pressor agents (norepinephrine and vasopressin) to maintain adequate hemodynamics. This pressor requirement subsequently increased the following day to three simultaneous pressor agents (norepinephrine, phenylephrine, and vasopressin) before later subsiding.

297 As COVID-19 infection has a strong association with coagulopathy (29,30), we focused our 298 study on the activity of enzymes involved in the clotting cascade and other trypsin-like proteases, which could be characterized by a similar array of target proteins, including but 299 300 not limited to coagulation enzymes and proteins such as fibrinogen. Thromboembolism and 301 reports of microvascular thrombi akin to a disseminated intravascular coagulation (DIC) 302 picture have been a common reported cause of death in patients admitted to the ICU with 303 severe COVID-19. Although the cause of death in Patient 3 was classified as septic shock, 304 the possible association between enhanced proteolytic activity, bacterial superinfection and 305 disease severity is nonetheless of interest and could point to i) the presence of additional 306 pathological mechanisms (i.e., proteolysis) that contribute to poor outcomes; ii) the 307 relationship between enzymatic activity patterns and bacterial superinfection that causes 308 further illness, in addition to that already seen with precedent viral infection.

The association between disease severity and -omics patterns is also supported by the measurements of other proteins that play a role in immunity and inflammation. For instance, the trends in expression of ficolin-1 and VEGFR2, and to some extent C-reactive protein (which showed a decrease over time in all four patients, much milder in Patient 3 though) correlate with the exacerbation of the inflammatory state of Patient 3 following diagnosis of bacterial superinfection. Ficolin-1 is a known activator of the complement system and innate

immunity through recognition of pathogen-associated molecular patterns (PAMPs) (31,32), 315 316 while VEGFR2 has been related to COVID-19 progression (33) as also suggested by the 317 hypothesis that the VEGF receptor activator (PMC18457) may serve as a biomarker for 318 detecting the progression of COVID-19 (34). In fact, the patient with the least severe course 319 of disease (Patient 2) had the lowest VEGFR2 intensity and, importantly, was the only patient 320 who was not diagnosed with ARDS. Patient 4, on the other hand, had rheumatoid arthritis 321 and subsequently greater VEGFR2 intensity. These observations highlight that the complexity 322 of the interplay between baseline comorbidities, severity of the disease and variability of the 323 features of immune and inflammatory responses prevents from interpreting conclusively the 324 expression trends of complement factors and warrants further research in the future.

325 There are some limitations of this study that need to be acknowledged. First, regarding the 326 clinically (obtained from the patient record) derived data, the low sample size of the studied 327 patient population and non-uniformity in the timing of some laboratory results hinders the 328 ability to make stronger inferences than are made here; the robustness of the presented 329 results would doubtlessly have been strengthened with a larger sample size and fewer 330 missing data. However, even with this very limited sample size we were able to make some 331 cautious conclusions as to new hypotheses of molecular mechanisms that might otherwise 332 not be recognized with a larger patient population. Second, regarding data drop-out, this was 333 a real-world observational study, and the clinical laboratory measurements and values reflect 334 patient management of severely ill COVID+ patients in the ICU. Third, in our analytical 335 protocol, the mass spectrometry approach was necessarily untargeted; if specific protein 336 systems and products of their degradation were targeted, it is possible that the potential 337 dysfunction in these systems (e.g., coagulation, complement, etc.) could be highlighted in 338 greater detail. Finally, when comparing and integrating proteomics and peptidomics data, the

availability of transcriptomics data, which were not part of the experimental design of this
 observational study, could add information on protein regulation, and help understand to a
 greater depth the impact of abnormal proteolysis and protein synthesis, breakdown, and
 turnover.

343 In conclusion, we demonstrate here that the analysis of the circulating proteome and peptidome, coupled with quantitation of enzymatic activity in plasma of COVID-19 patients, 344 345 provides additional data about the progression of the disease. Our approach could prove 346 particularly useful for achieving a more comprehensive description of the impairment of the activation and regulation of coagulation, a complex, protease-mediated system which plays 347 348 a critical role in the management of acute patients in the ICU. The association between 349 proteolytic activity and protease expression patterns achieved by mass spectrometry 350 investigation of plasma and bacterial superinfection in COVID-19 may also contribute to 351 anticipate the signs of possible superinfection and aid in the early diagnosis and delivery of a 352 timely therapy.

- 353
- 354

355 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

358

359 Funding

California Breast Cancer Research Program of the University of California, RGPO Grant
 R01RG3766 (R00RG2541) (to E.B.K.); US ARMY MEDICAL RESEARCH ACQUISITION
 ACTIVITY (USAMRAA) Award #W81XWH-17-2-0047 (to E.B.K.).

- 363
- 364

365 **References**

- Wiersing WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA (2020) 324(8):782-93.
- Osuchowski MF, Aletti F, Cavaillon JM, Flohé SB, Giamarellos-Bourboulis EJ, Huber-Lang M, Relja B, Skirecki T, Szabó A, Maegele M. SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. Shock (2020) 54(4):416-37.
- Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM, Weis S, Garcia-Salido A, Kox M, Cavaillon JM, Uhle F, Weigand MA, Flohé SB, Wiersinga WJ, Almansa R, de la Fuente A, Martin-Loeches I, Meisel C, Spinetti T, Schefold JC, Cilloniz C, Torres A, Giamarellos-Bourboulis EJ, Ferrer R, Girardis M, Cossarizza A, Netea MG, van der Poll T, Bermejo-Martín JF, Rubio I. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med (2021) 9(6):622-42.
- Lopes-Pacheco M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, Morales MM,
 Caruso Neves C, Rocco PRM. Pathogenesis of Multiple Organ Injury in COVID-19 and
 Potential Therapeutic Strategies. Front Physiol (2021);12:593223.
- Welte T, Ambrose LJ, Sibbring GC, Sheikh S, Müllerová H, Sabir I. Current evidence for
 COVID-19 therapies: a systematic literature review. Eur Respir Rev (2021)
 30(159):200384.
- Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T, Roche N. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J (2021) 57(4):2100048.
- Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, Arabi YM, 391 7. Loeb M, Ng Gong M, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Machado 392 393 F. Wunsch H, Crowther M, Cecconi M, Koh Y, Burry L, Chertow DS, Szczeklik W, Belley-Cote E, Greco M, Bala M, Zarychanski R, Kesecioglu J, McGeer A, Mermel L, Mammen 394 395 MJ, Nainan Myatra S, Arrington A, Kleinpell R, Citerio G, Lewis K, Bridges E, Memish ZA, Hammond N, Hayden FG, Alshahrani M, Al Duhailib Z, Martin GS, Kaplan LJ, 396 397 Coopersmith CM, Antonelli M, Rhodes A. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First 398 Update. Crit Care Med (2021) 49(3):e219-e234. 399
- 8. Tang Y, Liu J, Zhang D, Xu Ź, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol (2020) 11:1708.
- 402 9. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost (2020)
 403 18(9):2103-9.
- Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, Fernandez-Pittol M, Pitart C, Inciarte A, Bodro M, Morata L, Ambrosioni J, Grafia I, Meira F, Macaya I, Cardozo C, Casals C, Tellez A, Castro P, Marco F, García F, Mensa J, Martínez JA, Soriano A; COVID-19 Researchers Group. Incidence of coinfections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect (2021) 27(1):83-8.
- Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, Andreoli L,
 Franceschini F. Coagulation dysfunction in COVID-19: The interplay between
 inflammation, viral infection and the coagulation system. Blood Rev (2021) 46:100745.

- Aletti F, Conti C, Ferrario M, Ribas V, Bollen Pinto B, Herpain A, Post E, Romay Medina
 E, Barlassina C, de Oliveira E, Pastorelli R, Tedeschi G, Ristagno G, Taccone FS,
 Schmid-Schönbein GW, Ferrer R, De Backer D, Bendjelid K, Baselli G. ShockOmics:
 multiscale approach to the identification of molecular biomarkers in acute heart failure
 induced by shock. Scand J Trauma Resusc Emerg Med (2016);24:9.
- Aletti F, Maffioli E, Negri A, Santamaria MH, DeLano FA, Kistler EB, Schmid-Schönbein
 GW, Tedeschi G. Peptidomic Analysis of Rat Plasma: Proteolysis in Hemorrhagic Shock.
 Shock (2016) 45(5):540-54.
- 421 14. Bauzá-Martinez J, Aletti F, Pinto BB, Ribas V, Odena MA, Díaz R, Romay E, Ferrer R,
 422 Kistler EB, Tedeschi G, Schmid-Schönbein GW, Herpain A, Bendjelid K, de Oliveira E.
 423 Proteolysis in septic shock patients: plasma peptidomic patterns are associated with
 424 mortality. Br J Anaesth (2018) 121(5):1065-74.
- Aletti F, DeLano FA, Maffioli E, Mu H, Schmid-Schönbein GW, Tedeschi G, Kistler EB.
 Continuous enteral protease inhibition as a novel treatment for experimental trauma/hemorrhagic shock. Eur J Trauma Emerg Surg (2021). Online ahead of print.
- Maffioli E, Jiang Z, Nonnis S, Negri A, Romeo V, Lietz CB, Hook V, Ristagno G, Baselli
 G, Kistler EB, Aletti F, O'Donoghue AJ, Tedeschi G. High-Resolution Mass
 Spectrometry-Based Approaches for the Detection and Quantification of Peptidase
 Activity in Plasma. Molecules (2020) 25(18):4071.
- 432 17. Manguy J, Jehl P, Dillon ET, Davey NE, Shields DC, Holton TA. Peptigram: A Web433 Based Application for Peptidomics Data Visualization.J Proteome Res (2017) 16(2):712434 19
- 18. Cambiaghi A, Pinto BB, Brunelli L, Falcetta F, Aletti F, Bendjelid K, Pastorelli R, Ferrario
 M. Characterization of a metabolomic profile associated with responsiveness to therapy
 in the acute phase of septic shock. Sci Rep (2017) 7(1):9748.
- 438
 438
 439
 439
 439
 430
 440
 440
 440
 441
 441
 441
 441
 441
 442
 444
 444
 444
 444
 444
 445
 446
 446
 446
 447
 447
 448
 448
 449
 449
 449
 440
 440
 440
 440
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
- 20. Cambiaghi A, Díaz R, Martinez JB, Odena A, Brunelli L, Caironi P, Masson S, Baselli G,
 Ristagno G, Gattinoni L, de Oliveira E, Pastorelli R, Ferrario M. An Innovative Approach
 for The Integration of Proteomics and Metabolomics Data In Severe Septic Shock
 Patients Stratified for Mortality. Sci Rep (2018) 8(1):6681.
- Braga D, Barcella M, Herpain A, Aletti F, Kistler EB, Bollen Pinto B, Bendjelid K,
 Barlassina C. A longitudinal study highlights shared aspects of the transcriptomic response to cardiogenic and septic shock.Crit Care (2019) 23(1):414.
- Schuurman AR, Reijnders TDY, Kullberg RFJ, Butler JM, van der Poll T, Wiersinga WJ.
 Sepsis: deriving biological meaning and clinical applications from high-dimensional data.
 Intensive Care Med Exp (2021) 9(1):27.
- 452 23. Mangioni D, Peri AM, Rossolini GM, Viaggi B, Perno CF, Gori A, Bandera A. Toward
 453 rapid sepsis diagnosis and patient stratification: What's new from microbiology and omics
 454 Science. J Infect Dis (2020) 221(7):1039-47.
- 455 24. Messner CB et al. Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of
 456 COVID-19 Infection. Cell Syst (2020) 11(1):11-24.
- 457 25. Demichev V et al. A time-resolved proteomic and prognostic map of COVID-19. Cell Syst
 (2021) 12(8):780-94.
- 459 26. Haas P, Muralidharan M, Krogan NJ, Kaake RM, Hüttenhain R. Proteomic Approaches
 460 to Study SARS-CoV-2 Biology and COVID-19 Pathology. J Proteome Res (2021)
 461 20(2):1133-52.

- 462 27. McArdle A, Washington KE, Chazarin Orgel B, Binek A, Manalo DM, Rivas A, Ayres M,
 463 Pandey R, Phebus C, Raedschelders K, Fert-Bober J, Van Eyk JE. Discovery
 464 Proteomics for COVID-19: Where We Are Now. J Proteome Res (2021) Online ahead of
 465 print.
- Ranucci M, Sitzia C, Baryshnikova E, Di Dedda U, Cardani R, Martelli F, Corsi Romanelli
 M. Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and
 Fibrinolysis Leading the Outcome. J Clin Med (2020) 9(11):3487.
- 469 29. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost (2020)
 470 18(9):2103-9.
- 471 30. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated 472 intravascular coagulation. Int J Hematol (2020) 7:1–13.
- 31. Bidula S, Sexton DW, Schelenz S. Ficolins and the Recognition of Pathogenic
 Microorganisms: An Overview of the Innate Immune Response and Contribution of
 Single Nucleotide Polymorphisms. J Immunol Res (2019) 2019:3205072
- 476 32. Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS,
 477 Sacks S. Rationale for targeting complement in COVID-19. EMBO Mol Med (2020)
 478 12(8):e12642.
- 33. Birnhuber A, Fließer E, Gorkiewicz G, Zacharias M, Seeliger B, David S, Welte T,
 Schmidt J, Olschewski H, Wygrecka M, Kwapiszewska G. Between inflammation and
 thrombosis: endothelial cells in COVID-19. Eur Respir J (2021) 58(3):2100377.
- 482 34. Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H. VEGF-D: a novel biomarker for detection 483 of COVID-19 progression. Crit Care (2020) 24(1):373.

Covariate	Patient 1	Patient 2	Patient 3	Patient 4
BMI	29.40	23.66	32.14	30.19
Sex (M: male; F: female)	Μ	М	F	Μ
Survived (Yes / No)	Y	Y	Ν	Y
Admit to ICU from ED or Ward	Ward	ED	Ward	ED
ICU Length of Stay	17	3	16	9
Hospital Length of Stay	24	8	18	11
Self-described fitness level upon admission	Fit	Fit	Well	Fit
Modified Rankin Score on admission	No symptoms	No symptoms	No symptoms	No significant disability
Treatment in ICU				
Required pressors	Y		Y	Y
(ARDS) diagnosis	Y		Y	Y
Presence of another infection			Y*	
Antibiotics received: Azithromycin	Y	Y	Y	Y
Ceftriaxone	Y	Y		Y
Meropenem			Y	
Vancomycin			Y	Y
Piperacillin/Tazobactam			Y	Y

Table 2. Main Laboratory Data

Covariate	Patient 1	Patient 2	Patient 3	Patient 4
White Blood Count (10 ⁹ /I)				
Average [SD] (Range)	10.2 [1.5] (7.6-12.3)	8.4 [0.8] (7.4-9.6)	11.6 [4] (8.1-19.8)	7.7[1.7] (5.7-10.3)
Hemoglobin (g/dl)	. ,	· · · ·	. ,	, <i>,</i> ,
Average [SD] (Range)	13.0 [1.3] (12-15.4)	14.1 [1.2] (12.1-15.3)	9.4 [1.6] (6.4-11)	11.6 [1.6] (10.1-14.2)
Platelets (x10 ³ /µl)		, , , , , , , , , , , , , , , , , , ,	, , ,	, , , , , , , , , , , , , , , , , , ,
Average [SD] (Range)	404.3 [85.9] (223-468)	300.0 [124.3] (179-461)	294.9 [157.2] (170-608)	153.5[28.9] (113-183)
International Normalized Ratio	1.3 [0.1]	1.2 [0.1]	1.4 [0.0]	NC
Admission D-Dimer (ng/mL)	354	NC	699	NC

Average and range of laboratory blood tests from COVID-19 patients during their stay on ICU. Abbreviations: Standard Deviation (SD), Not collected (NC)







Days in ICU



Days in ICU



			P0/996	i nrombospondin-1
			P07225	Vitamin K-dependent protein S
			P00748	Coagulation factor XII +
L			P00747	Plasminogen
			P04070	Vitamin K-dependent protein C
			P0DJI8	Serum amyloid
_			P05452	Tetranectin
.				
5			075882	Attractin
			Q2M3G0	ATP-binding cassette sub-family B
			Q7Z434	Mitochondrial antiviral-signaling protein
Н			P16070	CD44 antigen
			P18428	Lipopolysaccharide-binding protein
			O60885	Bromodomain
			Q03169	Tumor necrosis factor alpha-induced protein 2
			O43866	CD5 antigen
			P10643	Complement C7
			P35968	Vascular endothelial growth factor receptor +
			000602	Ficolin-1 +
			P0C0L5	Complement C4-B
1-			Q9UEW3	Macrophage receptor
			P20851	C4b-binding protein beta chain
			P02745	Complement C1q subcomponent subunit A
	-Ч-		P02746	Complement C1q subcomponent subunit B
			P02747	Complement C1q subcomponent subunit C
			P01024	Complement C3
			P08571	Monocyte differentiation antigen CD14
			P04003	C4b-binding protein alpha chain
			P0C0L4	Complement C4-A
			P09871	Complement C1s
			P13671	Complement C6



